Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06	Engineering Information Encompass files have new names
NEWS	4	Feb 16	TOXLINE no longer being updated
NEWS	5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07	DGENE Reload
NEWS	8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS	9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI

NEWS EXPRESS	July 11 CURRENT WINDOWS VERSION IS V6.0b, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:42:16 ON 19 JUL 2001

=> file medline, uspat, hcaplus, dgene, wpids, embase, scisearch, frosti, fsta, jicst, japio, biotechds, cen, ceaba, biobusiness

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 15:42:53 ON 19 JUL 2001

FILE 'USPATFULL' ENTERED AT 15:42:53 ON 19 JUL 2001

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 15:42:53 ON 19 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPIDS' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'FROSTI' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'BIOTECHDS' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'CEN' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (c) 2001 DECHEMA eV

FILE 'BIOBUSINESS' ENTERED AT 15:42:53 ON 19 JUL 2001
COPYRIGHT (C) 2001 Biological Abstracts, Inc. (BIOSIS)

=> s autotaxin or ATX

  11 FILES SEARCHED...
L1   1407 AUTOTAXIN OR ATX

=> s l1 and purifi?

  11 FILES SEARCHED...
L2   85 L1 AND PURIFI?

=> s l2 and method

L3   41 L2 AND METHOD

=> s l3 and phosphodiesterase

L4   2 L3 AND PHOSPHODIESTERASE

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 2 USPATFULL
TI **Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
AB The present invention relates, in general, to **autotaxin**. In particular, the present invention relates to a DNA segment encoding **autotaxin**; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a **method** of producing **autotaxin**; antibodies to **autotaxin**; and identification of functional domains in **autotaxin**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:84405 USPATFULL
TITLE:	**Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
INVENTOR(S):	Stracke, Mary, Rockville, MD, United States Liotta, Lance, Potomac, MD, United States Schiffmann, Elliott, Chevy Chase, MD, United States Krutzch, Henry, Bethesda, MD, United States Murata, Jun, Toyama, Japan
PATENT ASSIGNEE(S):	The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6084069		20000704
APPLICATION INFO.:	US 1997-977221		19971124 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-346455, filed on 28 Nov 1994, now patented, Pat. No. US 5731167 which is a continuation-in-part of Ser. No. US 1994-249182, filed on 25 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-822043, filed on 17 Jan 1992, now patented, Pat. No. US 5449753		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prouty, Rebecca E.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Morgan & Finnegan, L.L.P.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	2608		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 USPATFULL
TI **Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
AB The present invention relates, in general, to **autotaxin**. In particular, the present invention relates to a DNA segment encoding **autotaxin**; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a **method** of producing **autotaxin**; antibodies to **autotaxin**; and identification of functional domains in **autotaxin**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:30878 USPATFULL
TITLE:	**Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
INVENTOR(S):	Stracke, Mary, Rockville, MD, United States Liotta, Lance, Potomac, MD, United States Schiffmann, Elliott, Chevy Chase, MD, United States Krutzch, Henry, Bethesda, MD, United States Murata, Jun, Toyama, Japan
PATENT ASSIGNEE(S):	The United States of America as represented by the

Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731167		19980324
APPLICATION INFO.:	US 1994-346455		19941128 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-249182, filed on 25 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-822043, filed on 17 Jan 1992, now patented, Pat. No. US 5449753
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Morgan & Finnegan, L.L.P.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1953
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:42:16 ON 19 JUL 2001)

FILE 'MEDLINE, USPATFULL, HCAPLUS, DGENE, WPIDS, EMBASE, SCISEARCH, FROSTI, FSTA, JICST-EPLUS, JAPIO, BIOTECHDS, CEN, CEABA-VTB, BIOBUSINESS'
ENTERED AT 15:42:53 ON 19 JUL 2001
L1 1407 S AUTOTAXIN OR ATX
L2 85 S L1 AND PURIFI?
L3 41 S L2 AND METHOD
L4 2 S L3 AND PHOSPHODIESTERASE

=> s l3 and cell motility stimulating peptide

11 FILES SEARCHED...
L5 0 L3 AND CELL MOTILITY STIMULATING PEPTIDE

=> s cell motility stimulating peptide

14 FILES SEARCHED...
L6 0 CELL MOTILITY STIMULATING PEPTIDE

=> s s l1 and cell motility

MISSING OPERATOR S L1
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and cell motility

L7 106 L1 AND CELL MOTILITY

=> s tyrosine

L8 371205 TYROSINE

=> s l8 and methionine

L9 29231 L8 AND METHIONINE

```
=> s l9 and arginine

L10      17968 L9 AND ARGININE

=> s l10 and proline

L11      13455 L10 AND PROLINE

=> s Tyr-Met-Arg-Pro-Val-Gyr-Pro-Thr-Lys-Thr-Phe-Pro-Asn

  12 FILES SEARCHED...
L12          0 TYR-MET-ARG-PRO-VAL-GYR-PRO-THR-LYS-THR-PHE-PRO-ASN

=> s l11 and l7

L13          0 L11 AND L7

=>  d his


     (FILE 'HOME' ENTERED AT 15:42:16 ON 19 JUL 2001)

     FILE 'MEDLINE, USPATFULL, HCAPLUS, DGENE, WPIDS, EMBASE, SCISEARCH,
     FROSTI, FSTA, JICST-EPLUS, JAPIO, BIOTECHDS, CEN, CEABA-VTB,
BIOBUSINESS'
     ENTERED AT 15:42:53 ON 19 JUL 2001
L1         1407 S AUTOTAXIN OR ATX
L2           85 S L1 AND PURIFI?
L3           41 S L2 AND METHOD
L4            2 S L3 AND PHOSPHODIESTERASE
L5            0 S L3 AND CELL MOTILITY STIMULATING PEPTIDE
L6            0 S CELL MOTILITY STIMULATING PEPTIDE
L7          106 S L1 AND CELL MOTILITY
L8       371205 S TYROSINE
L9        29231 S L8 AND METHIONINE
L10       17968 S L9 AND ARGININE
L11       13455 S L10 AND PROLINE
L12           0 S TYR-MET-ARG-PRO-VAL-GYR-PRO-THR-LYS-THR-PHE-PRO-ASN
L13           0 S L11 AND L7

=> s l4 ti abs ibib tot

MISSING OPERATOR L4 TI
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l3 ti abs ibib tot


L3   ANSWER 1 OF 41     MEDLINE
TI   A simple biochemical method in the search for bioactive
     polypeptides in a sea anemone (Anemonia sulcata).
AB   The sea anemone Anemonia sulcata is a well-known natural source of supply
     of biologically active polypeptides. So far, five toxins, ATX I,
     II, III, IV and AS V, several polyvalent protease inhibitors, an elastase
     inhibitor, two blood pressure-depressive polypeptides and very recently
     peptides that inhibit competitively the binding of 125I-dendrotoxin to
rat
     brain membranes and block the voltage-sensitive K+ channels, have been
     isolated from it. The sea anemone toxins (especially toxin II of A.
     sulcata, ATX II) are very important tools in neurophysiological
     and pharmacological research, and their structure-function relationship
     has been investigated. Because of the great scientific value of the sea
```

anemone toxins a simplification of their **purification** procedure was elaborated.

ACCESSION NUMBER: 971[redacted]56 MEDLINE
DOCUMENT NUMBER: 97179756 PubMed ID: 9027992
TITLE: A simple biochemical **method** in the search for bioactive polypeptides in a sea anemone (Anemonia sulcata).
AUTHOR: Sanchez J; Bruhn T; Aneiros A; Wachter E; Beress L
CORPORATE SOURCE: Institut fur Toxikologie, Klinikum der Christian-Albrechts-Universitat zu Kiel, Germany.
SOURCE: TOXICON, (1996 Nov-Dec) 34 (11-12) 1361-6.
Journal code: VWT; 1307333. ISSN: 0041-0101.
PUB. COUNTRY: ENGLAND: United Kingdom
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199705
ENTRY DATE: Entered STN: 19970514
Last Updated on STN: 19970514
Entered Medline: 19970508

L3 ANSWER 2 OF 41 MEDLINE
TI Immuno-enhancing activity of the amino-terminal domain of human prealbumin: isolation, characterization and synthesis.
AB A decapeptide isolated from highly **purified** preparations of human prealbumin was able to restore azathioprine (Az) sensitivity, a property of a sub-class of T-lymphocytes, to the spleen rosette-forming cells (RFC) of adult thymectomized (**ATx**) mice in vitro. The peptide was sequenced by the Edman **method** and shown to correspond to the ten amino-terminal residues of prealbumin, Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys. Synthesis of this peptide by solid phase methodology confirmed its activity both in vitro and in vivo. Synthesis of a number of structural analogues indicated that the amino-terminal deca, undeca and dodecapeptides of prealbumin as well as some of their derivatives were also able to restore Az sensitivity to RFC in vitro and in vivo. The Cys10 residue and the Glu7 residues both contributed significantly to potency in vitro. Removal of up to three amino acids from the N-terminus of the decapeptide led to a progressive loss of activity. The data indicates that the ability of human prealbumin to restore the Az sensitivity to the RFC of adult Tx mice is intrinsic to the protein and resides in the amino-terminal domain of the molecule.

ACCESSION NUMBER: 87278738 MEDLINE
DOCUMENT NUMBER: 87278738 PubMed ID: 3610418
TITLE: Immuno-enhancing activity of the amino-terminal domain of human prealbumin: isolation, characterization and synthesis.
AUTHOR: Burton P M; Horner B L; Jones G H; Lin T; Nestor J J Jr; Newman S R; Parks T L; Smith A J; White A
SOURCE: INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1987) 9 (3) 297-305.
Journal code: GRI; 7904799. ISSN: 0192-0561.
PUB. COUNTRY: ENGLAND: United Kingdom
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198708
ENTRY DATE: Entered STN: 19900305
Last Updated on STN: 19900305
Entered Medline: 19870828

L3 ANSWER 3 OF 41 USPATFULL
TI NF-AT polypeptides and polynucleotides
AB The invention provides novel polypeptides which are associated with the

transcription complex NF-AT, polynucleotides encoding such polypeptides,
antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides. The invention also provides methods for detecting T cells (including activated T cells) in a cellular sample, methods for treating hyperactive or hypoactive T cell conditions, methods for screening for immunomodulatory agents, methods for diagnostic staging of lymphocyte differentiation, methods for producing NF-AT proteins for use as research or diagnostic reagents, methods for producing antibodies reactive with the novel polypeptides, and methods for producing transgenic nonhuman animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:4455 USPATFULL
TITLE:	NF-AT polypeptides and polynucleotides
INVENTOR(S):	Crabtree, Gerald R., Woodside, CA, United States Northrop, Jeffrey P., Cupertino, CA, United States Ho, Steffan N., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Board of Trustees of the Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171781	B1	20010109
APPLICATION INFO.:	US 1998-49691		19980327 (9)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-260174, filed on 13 Jun 1994 Continuation-in-part of Ser. No. US 1993-124981, filed on 20 Sep 1993, now patented, Pat. No. US 5837840
DOCUMENT TYPE:	Patent
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Schwartzman, Robert A.
LEGAL REPRESENTATIVE:	Foley, Hoag & Eliot, LLP, Clauss, Isabelle M., Vincent, Matthew P.
NUMBER OF CLAIMS:	90
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT:	4707

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 41 USPATFULL
TI **Method** for producing a **purified** hemoglobin product
AB A **method** for producing a **purified** hemoglobin product includes loading a hemoglobin solution onto an anion exchange chromatography column. At least one tris(hydroxymethyl) aminomethane acetate buffer solution is injected into the column. The buffer solution has a pH lower than that of the column, whereby a **purified** hemoglobin product elutes from the column. In one embodiment, the hemoglobin solution initially can be equilibrated at a pH of greater than about 8.7. In another embodiment, contaminants can be removed by equilibrating the column with at least about eleven column void volumes of buffer solution at an intermediate pH of between about 8.2 and about 8.6, to thereby form a stepped pH gradient. In still another embodiment,

all buffer solutions employed are tris(hydroxymethyl) aminomethane acetate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:157556 USPATFULL

TITLE: **Method** for producing a **purified** hemoglobin product

INVENTOR(S): Houtchens, Robert A., Milford, MA, United States
Rausch, Carl W., Medford, MA, United States

PATENT ASSIGNEE(S): Biopure Corporation, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150507		20001121
APPLICATION INFO.:	US 1998-113953		19980710 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-473497, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-458916, filed on 2 Jun 1995, now patented, Pat. No. US 5840852 which is a continuation of Ser. No. US 1995-409337, filed on 23 Mar 1995, now patented, Pat. No. US 5854209

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 2031
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 41 USPATFULL
TI Endo-xyloglucan transferase
AB Endo-xyloglucan transferases responsible for growth of plant cell wall, genes coding for the enzymes, a **method** of transferring xyloglucan molecules by using the enzyme, and methods of using the gene are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:124776 USPATFULL

TITLE: Endo-xyloglucan transferase

INVENTOR(S): Nishitani, Kazuhiko, Kagoshima, Japan
Okazawa, Kazuhide, Otsu, Japan
Asada, Kiyozo, Shiga-ken, Japan
Kato, Ikunoshin, Uji, Japan

PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Kyoto, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6120998		20000919
APPLICATION INFO.:	US 1998-52085		19980331 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-445533, filed on 22 May 1995, now patented, Pat. No. US 5840550 which is a division of Ser. No. US 1995-381280, filed on 31 Jan 1995, now patented, Pat. No. US 5516694 which is a continuation of Ser. No. US 1993-37281, filed on 26 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-929513, filed on 14 Aug 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-98506	19920326
	JP 1992-217489	19920724
	JP 1993-31163	19930128

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schmidt, Melissa
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack, L.L.P.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 41 USPATFULL
TI **Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
AB The present invention relates, in general, to **autotaxin**. In particular, the present invention relates to a DNA segment encoding **autotaxin**; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a **method** of producing **autotaxin**; antibodies to **autotaxin**; and identification of functional domains in **autotaxin**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:84405 USPATFULL
TITLE: **Autotaxin**: motility stimulating protein useful in cancer diagnosis and therapy
INVENTOR(S): Stracke, Mary, Rockville, MD, United States
Liotta, Lance, Potomac, MD, United States
Schiffmann, Elliott, Chevy Chase, MD, United States
Krutzch, Henry, Bethesda, MD, United States
Murata, Jun, Toyama, Japan
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6084069		20000704
APPLICATION INFO.:	US 1997-977221		19971124 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-346455, filed on 28 Nov 1994, now patented, Pat. No. US 5731167 which is a continuation-in-part of Ser. No. US 1994-249182, filed on 25 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-822043, filed on 17 Jan 1992, now patented, Pat. No. US 5449753
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Morgan & Finnegan, L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2608
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 41 USPATFULL
TI Non-depleting anti-CD4 monoclonal antibodies and tolerance induction
AB Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal

antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depleting CD8 monoclonal antibody may be administered prior to non-depleting antibodies.

ACCESSION NUMBER: 2000:53740 USPATFULL
TITLE: Non-depleting anti-CD4 monoclonal antibodies and tolerance induction
INVENTOR(S): Cobbold, Stephen Paul, Cambridge, United Kingdom
Waldmann, Herman, Cambridge, United Kingdom
PATENT ASSIGNEE(S): Glaxo Wellcome Inc., Research Triangle Park, NC, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6056956		20000502
APPLICATION INFO.:	US 1995-470421		19950606 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-289532, filed on 12 Aug 1994, now patented, Pat. No. US 5690933 which is a continuation of Ser. No. US 1994-181170, filed on 13 Jan 1994, now abandoned which is a continuation of Ser.
No. US 1993-47344, filed on 29 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-768868, filed on 27 Jul 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-12497	19890531

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Gambel, Phillip
LEGAL REPRESENTATIVE: Nixon & Vanderhye P.C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1269

L3 ANSWER 8 OF 41 USPATFULL
TI **Method** of making monoclonal antibodies using polymorphic transgenic animals
AB The invention relates to a **method** for making monoclonal antibodies having pre-defined specificity for an epitope characteristic of or unique to a single form of a polymorphic protein. The **method** includes constructing a first transgenic animal to express a first form of a polymorphic protein encoded by a first allele of a gene encoding the protein; constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein; and immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope peculiar to the second form of the polymorphic protein. The invention further includes hybridoma cells secreting a monoclonal antibody specific for the second form of the protein. The invention is particularly advantageous in the context of making monoclonal antibodies and derivative reagents specifically identifying polymorphic blood group proteins, such as the Duffy gp-Fy protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:50882 USPATFULL
TITLE: **Method** of making monoclonal antibodies using

polymorphic transgenic animals
INVENTOR(S): Reid, Marion E., New York, NY, United States
PATENT ASSIGNEE(S): New York Blood Center, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054632		20000425
APPLICATION INFO.:	US 1996-749527		19961115 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hauda, Karen
LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1,5
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1077
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 41 USPATFULL
TI Polypeptides implicated in the expression of resistance to glycopeptides, in particular in gram-positive bacteria, nucleotide sequence coding for these polypeptides and use for diagnosis
AB The invention relates to compositions and nucleic acids encoding polypeptides involved in the expression of resistance to glycopeptides, in particular to vancomycin and/or teicoplanin. The invention also relates to vectors containing said nucleic acids, transformed host cells
and their use for the diagnosis of resistance to glycopeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:4671 USPATFULL
TITLE: Polypeptides implicated in the expression of resistance
to glycopeptides, in particular in gram-positive bacteria, nucleotide sequence coding for these polypeptides and use for diagnosis
INVENTOR(S): Arthur, Michel, Paris, France
Dukta-Malen, Sylvie, Fresnes, France
Molinas, Catherine, Paris, France
Courvalin, Patrice, Paris, France
PATENT ASSIGNEE(S): Institut Pasteur, Paris Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013508		20000111
APPLICATION INFO.:	US 1997-980357		19971128 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286819, filed on 5 Aug 1994, now patented, Pat. No. US 5871910 which is a continuation of Ser. No. US 1993-174682, filed on 28 Dec 1993, now abandoned which is a continuation of Ser.
No. US 917146

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1990-13579	19901031

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Horlick, Kenneth R.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 94 Drawing Page(s)
LINE COUNT: 5717
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 41 USPATFULL
TI Agricultural pesticide formulations
AB The present invention relates generally to the **method** for the production of liposomal microencapsulated boron-containing products to be used for agricultural formulations. More specifically, a new **method** of production of liposomal microencapsulated is disclosed for active agents such as pesticides. A lecithin is mixed with an organic solvent in a certain proportion so as to provide solutions with varied levels of solubilized lecithin. The particular solvent being used will depend on the amount of active agent (AA) desired in the final solution. The formulation of the lecithin/organic solvent mixture is then allowed to settle. After settling, the top layer is separated and saved, while the bottom layer is discarded. An AA is then added to form a concentrate that is added to water for vesicle formation. Boron-containing materials formulated according to the invention may now be applied to agricultural field crops and fruits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:117035 USPATFULL
TITLE: Agricultural pesticide formulations
INVENTOR(S): Milne, Christopher G., Greenback, TN, United States
Shelby, Jr., Paulus P., Knoxville, TN, United States
PATENT ASSIGNEE(S): Agri-Tek, Inc., Greenback, TN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5958463		19990928
APPLICATION INFO.:	US 1996-754859		19961122 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-248480, filed on 24 May 1994, now abandoned which is a continuation of Ser. No. US 1993-67530, filed on 23 May 1993, now abandoned which is a continuation of Ser. No. US 1991-737202, filed on 29 Jul 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Pak, John
LEGAL REPRESENTATIVE: Markva, Neil F.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 41 USPATFULL
TI **Method** for producing a stable polymerized hemoglobin blood-substitute
AB A **method** for producing a stable polymerized hemoglobin blood-substitute from blood. The **method** of this invention includes mixing blood with an anticoagulant to form a blood solution, washing the red blood cells in the blood solution and then separating the washed red blood cells from the white blood cells. This **method** also includes disrupting the red blood cells to release hemoglobin and form a hemoglobin solution, which is then treated by high performance liquid chromatography to form a hemoglobin eluate. The hemoglobin eluate is then deoxygenated, contacted with a first sulfhydryl compound to form an oxidation-stabilized deoxygenated hemoglobin solution, and mixed with a cross-linking agent to form a

polymerization reaction mixture, which is then polymerized. The polymerized hemoglobin solution is then diafiltered with a physiologic solution and with a sulfhydryl compound, whereby the polymerized hemoglobin solution is made physiologically acceptable, and whereby the sulfhydryl compound scavenges oxygen, to form a stable polymerized hemoglobin blood-substitute.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:113866 USPATFULL
TITLE:	**Method** for producing a stable polymerized hemoglobin blood-substitute
INVENTOR(S):	Rausch, Carl W., Medford, MA, United States Gawryl, Maria S., Charlestown, MA, United States Houtchens, Robert A., Milford, MA, United States Laccetti, Anthony J., North Andover, MA, United States Light, William R., Natick, MA, United States
PATENT ASSIGNEE(S):	Biopure Corporation, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955581		19990921
APPLICATION INFO.:	US 1995-484775		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-209949, filed on 11 Mar 1994, now patented, Pat. No. US 5618919 And a continuation-in-part of Ser. No. US 1995-458916, filed on 2 Jun 1995 which is a continuation of Ser. No. US 1995-409337, filed on 23 Mar 1995 , said Ser. No. US 1994-209949, filed on 11 Mar 1994 which is a continuation of Ser. No. US 1992-820153, filed on 13 Jan 1992, now patented, Pat. No. US 5296465 which is a continuation of Ser. No. US 1987-119121, filed on 10 Nov 1987, now patented, Pat. No. US 5084558 which is a continuation-in-part of Ser. No. US 1987-107421, filed on 13 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-928345, filed on 10 Nov 1986, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Tsang, Cecilia J.
ASSISTANT EXAMINER:	Gupta, Anish
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	2198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 41 USPATFULL

TI Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof

AB This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM') antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a **method** of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:92535 USPATFULL

TITLE: Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof

INVENTOR(S): Israeli, Ron S., Staten Island, NY, United States
Heston, Warren D. W., New York, NY, United States
Fair, William R., New York, NY, United States

PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5935818		19990810
APPLICATION INFO.:	US 1995-394152		19950224 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Caputa, Anthony C.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 101 Drawing Figure(s); 89 Drawing Page(s)
LINE COUNT: 4384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 41 USPATFULL
TI Selective binding complementary oligonucleotides
AB In a matched pair of oligonucleotides (ODNS) each member of the pair is complementary or substantially complementary in the Watson Crick sense to a target sequence of duplex nucleic acid where the two strands of the target sequence are themselves complementary to one another. The ODNs include modified bases of such nature that the modified base forms a stable hydrogen bonded base pair with the natural partner base, but does not form a stable hydrogen bonded base pair with its modified partner. This is accomplished when in a hybridized structure the modified base is capable of forming two or more hydrogen bonds with its natural complementary base, but only one hydrogen bond with its modified partner. Due to the lack of stable hydrogen bonding with each other, the matched pair of oligonucleotides have a melting temperature under physiological or substantially physiological conditions of approximately 40.degree. C. or less. However each of the matched ODN pair of the invention forms a substantially stable hybrid with the target sequence in each strand of the duplex nucleic acid. The hybrids of target duplex nucleic acids formed with the ODN pairs of the invention are useful for gene mapping and in diagnostic and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:67359 USPATFULL
TITLE: Selective binding complementary oligonucleotides
INVENTOR(S): Kutyavin, Igor V., Bothell, WA, United States
Woo, Jinsuk, Lynnwood, WA, United States
Lukhtanov, Eugeny A., Bothell, WA, United States
Meyer, Jr., Rich B., Bothell, WA, United States
Gamper, Howard B., Woodinville, WA, United States
PATENT ASSIGNEE(S): Epoch Pharmaceuticals, Inc., Bothell, WA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5912340		19990615

APPLICATION INFO.: US 1995-539097 19951004 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Houtteman, Scott W.
LEGAL REPRESENTATIVE: Klein & Szekeres, LLP
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 1639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 41 USPATFULL
TI Genetic sequences encoding flavonoid pathway enzymes and uses therefor
AB The present invention relates to a nucleic acid isolate comprising a sequence of nucleotides encoding, or complementary to a sequence encoding, a dihydrokaempferol (DHK) hydroxylating enzyme or derivative or part thereof. The present invention also relates to transgenic plants carrying and expressing the above mentioned nucleic acid material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:7474 USPATFULL
TITLE: Genetic sequences encoding flavonoid pathway enzymes and uses therefor
INVENTOR(S): Holton, Timothy Albert, Northcote, Australia
Cornish, Edwina Cecily, Upper Beaconsfield, Australia
Kovacic, Filippa, Preston, Australia
Tanaka, Yoshikazu, Rosanna, Australia
Lester, Diane Ruth, Triabunna, Australia
PATENT ASSIGNEE(S): International Flower Developments Pty. Ltd., Victoria, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5861487		19990119
APPLICATION INFO.:	US 1995-502046		19950714 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-285309, filed on 3 Aug 1994, now patented, Pat. No. US 5569832 which is a continuation of Ser. No. US 1992-912900, filed on 13 Jul 1992, now patented, Pat. No. US 5349125

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1991-7173	19910711
	AU 1992-923	19920217

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Chereskin, Che S.
LEGAL REPRESENTATIVE: Scully, Scott, Murphy & Presser
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 39 Drawing Page(s)
LINE COUNT: 2012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 41 USPATFULL
TI Endo-xyloglucan transferase
AB Endo-xyloglucanase transferases responsible for growth of plant cell wall, genes coding for the enzymes, a **method** of transferring xyloglucan molecules by using the enzyme, and methods of using the gene are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:147272 USPATFULL

TITLE: Endo-xyloglucan transferase
INVENTOR(S): [redacted]shitani, Kazuhiko, Kagoshima, Japan
[redacted]azawa, Kazuhide, Otsu, Japan
Asada, Kiyozo, Shiga-ken, Japan
Kato, Ikunoshin, Uji, Japan
PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Kyoto-fu, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840550		19981124
APPLICATION INFO.:	US 1995-445533		19950522 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-381280, filed on 31 Jan 1995, now patented, Pat. No. US 5516694 which is a continuation of Ser. No. US 1993-37281, filed on 26 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-929513, filed on 14 Aug 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-98506	19920326
	JP 1992-217489	19920724
	JP 1993-31163	19930128

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Hobbs, Lisa J.
LEGAL REPRESENTATIVE: Wenderoth, Lind & Ponack
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 2941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 41 USPATFULL
TI **Method** for producing a stable polymerized hemoglobin blood-substitute
AB A **method** for producing a stable polymerized hemoglobin blood-substitute from blood. The **method** of this invention includes mixing blood with an anticoagulant to form a blood solution, washing the red blood cells in the blood solution and then separating the washed red blood cells from the white blood cells. This **method** also includes disrupting the red blood cells to release hemoglobin and form a hemoglobin solution, which is then treated by high performance liquid chromatography to form a hemoglobin eluate. The hemoglobin eluate is then deoxygenated, contacted with a first sulfhydryl compound to form an oxidation-stabilized deoxygenated hemoglobin solution, and mixed with a cross-linking agent to form a polymerization reaction mixture, which is then polymerized. The polymerized hemoglobin solution is then diafiltered with a physiologic solution and with a sulfhydryl compound, whereby the polymerized hemoglobin solution is made physiologically acceptable, and whereby the sulfhydryl compound scavenges oxygen, to form a stable polymerized hemoglobin blood-substitute.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:54861 USPATFULL
TITLE: **Method** for producing a stable polymerized hemoglobin blood-substitute
INVENTOR(S): Rausch, Carl W., Medford, MA, United States
Gawryl, Maria S., Charlestown, MA, United States

	Houtchens, Robert A., Milford, MA, United States [redacted]accetti, Anthony J., North Andover, MA, United States [redacted]ight, William R., Natick, MA, United States
PATENT ASSIGNEE(S): (U.S.	Biopure Corporation, Cambridge, MA, United States corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5753616		19980519
APPLICATION INFO.:	US 1995-478004		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-484775, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-458916, filed on 2 Jun 1995 which is a continuation of Ser. No. US 1995-409337, filed on 23 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-209949, filed on 11 Mar 1994, now patented, Pat. No. US 5618919 which is a continuation of Ser. No. US 1992-820153, filed on 13 Jan 1992, now patented, Pat. No. US 5296465 which is a continuation of Ser. No. US 1987-119121, filed on 10 Nov 1987, now patented, Pat. No. US 5084558 which is a continuation-in-part of Ser. No. US 1987-107421, filed on 13 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-928345, filed on 10 Nov 1986, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

<------User Break------>